Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub‐analysis from the XAPASS study

Figures

• 

  FIGURE 1. Low‐, moderate‐, high‐, and very‐high‐risk groups. 1. Low‐risk group = 0 risk factors; 2. Moderate‐risk group = 1 risk factor (age ≥75 years); 3. Moderate‐risk group = 1 risk factor (renal impairment [CrCl <50 ml/min]); 4. Moderate‐risk group = 1 risk factor (low body weight [≤50 kg]); 5. High‐risk group = 2 risk factors (age ≥75 years + CrCl <50 ml/min); 6. High‐risk group = 2 risk factors (age ≥75 years + weight ≤50 kg); 7. High‐risk group = 2 risk factors (CrCl <50 ml/min + weight ≤50 kg); 8. Very‐high‐risk group = 3 risk factors (age ≥75 years + CrCl <50 ml/min + weight ≤50 kg). CrCl, creatinine clearance

• 

  FIGURE 2. Patient selection flowchart. CrCl, creatinine clearance

• 

  FIGURE 3. Cumulative incidence of (A) any bleeding, (B) major bleeding, (C) stroke/non‐CNS SE/MI, and (D) all‐cause mortality by risk group. CNS, central nervous system; MI, myocardial infarction; SE, systemic embolism

• 

  FIGURE 4. Univariable and multivariable analysis for risk of major bleeding and stroke/non‐CNS SE/MI by risk group (low, moderate, high, and very high). Multivariable analysis adjusted by sex, initial dose, hypertension, diabetes mellitus, congestive heart failure, prior ischemic stroke/TIA, vascular disease, hepatic dysfunction, and oral antiplatelet use at study enrollment. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; MI, myocardial infarction; SE, systemic embolism; TIA, transient ischemic attack

• 

  FIGURE 5. Univariable and multivariable analysis for risk of major bleeding and stroke/non‐CNS SE/MI by risk factor (age ≥75 years [elderly], renal impairment [CrCl <50 ml/min], and low body weight [≤50 kg]). Multivariable analysis adjusted by sex, initial dose, hypertension, diabetes mellitus, congestive heart failure, prior ischemic stroke/TIA, vascular disease, hepatic dysfunction, and oral antiplatelet use at study enrollment. 1. Low‐risk group = 0 risk factors; 2. Moderate‐risk group = 1 risk factor (age ≥75 years); 3. Moderate‐risk group = 1 risk factor (CrCl <50 ml/min); 4. Moderate‐risk group = 1 risk factor (weight ≤50 kg); 5. High‐risk group = 2 risk factors (age ≥75 years + CrCl <50 ml/min); 6. High‐risk group = 2 risk factors (age ≥75 years + weight ≤50 kg); 7. High‐risk group = 2 risk factors (CrCl <50 ml/min + weight ≤50 kg); 8. Very‐high‐risk group = 3 risk factors (age ≥75 years + CrCl <50 ml/min + weight ≤ 50 kg). CI, confidence interval; CNS, central nervous system; CrCl, creatinine clearance; HR, hazard ratio; LBW, low body weight; MI, myocardial infarction; RI, renal impairment; SE, systemic embolism; TIA, transient ischemic attack